Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  28 (2024)
Volume  27 (2023)
Volume  26 (2022)
Volume  25 (2021)
Volume  24 (2020)
Volume  23 (2019)
Volume  22 (2018)
Volume  21 (2017)
Volume  20 (2016)
Volume  19 (2015)
Volume  18 (2014)
Volume  17 (2013)
Volume  16 (2012)
Volume  15 (2011)
Volume  14 (2010)
Volume  13 (2009)
Volume  12 (2008)
Volume  11 (2007)
Volume  10 (2006)
Volume  9 (2005)
Volume  8 (2004)
Related articles

VOLUME 26 , ISSUE 10 ( October, 2022 ) > List of Articles

EDITORIAL

Anti-cytokine Therapy in Hospitalized Patients with COVID-19: The Jury is Out

Sunil Kumar Garg

Keywords : Anakinra, Anti-cytokine therapy, Anti-inflammatory therapy, Corona virus-2019, Cytokine storm, Interleukin 1, Interleukin receptor antagonist, Interleukin 6 receptor antagonists, Inflammatory biomarker, Tocilizumab

Citation Information : Garg SK. Anti-cytokine Therapy in Hospitalized Patients with COVID-19: The Jury is Out. Indian J Crit Care Med 2022; 26 (10):1069-1071.

DOI: 10.5005/jp-journals-10071-24336

License: CC BY-NC 4.0

Published Online: 30-09-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract
PDF Share
  1. Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P, et al. Effect of anakinra on mortality in patients with COVID-19: A systematic review and patient-level meta-analysis. Lancet Rheumatol 2021;3: e690–e697. DOI: 10.1016/S2665-9913(21)00216-2.
  2. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical, and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chem Lab Med 2020; 58:1021–1028. DOI: 10.1515/cclm-2020-0369.
  3. The National Institutes of Health. COVID-19 treatment guidelines. Available at: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/kinase-inhibitors/. Accessed on: 9 September 2022.
  4. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021;384(8):693–704. DOI: 10.1056/NEJMoa2021436. Accessed on: 9 September 2022.
  5. REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, D Nicho AD, et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med 2021;384(16): 1491–1502. DOI: 10.1056/NEJMoa2100433.
  6. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 2021;397(10285):1637–1645. DOI: 10.1016/S0140-6736(21)00676-0.
  7. The REMAP-CAP Investigators, Derde LPG. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19: The REMAP-CAP COVID-19 immune modulation therapy domain randomized clinical trial. medRxiv 2021: 2021.06.18.21259133. https://doi.org/10.1101/2021.06.18.21259133.
  8. Rosas IO, Diaz G, Gottlieb RL, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: A randomized clinical trial. Intensive Care Med 2021;47(11):1258–1270. DOI: 10.1007/s00134-021-06507-x.
  9. Kyriazopoulou E, Poulakou G, Milionis H, Lobo SM, Robinson P, Hunter BD, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: A double-blind, randomized controlled phase 3 trial. Nat Med 2021; 27(10):1752–1760. DOI: 10.1038/s41591-021-01499-z.
  10. CORIMUNO-19 Collaborative Group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): A randomised controlled trial. Lancet Respir Med 2021;9(3):295–304. DOI: 10.1016/S2213-2600(20) 30556-7.
  11. Caricchio R, Abbate A, Gordeev I, Meng J, Hsue PY, Neogi T, et al. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: A randomized clinical trial. JAMA 2021;326(3):230–239. DOI: 10.1001/jama.2021.9508.
  12. Ozkan F, Sari S. Comparison of anakinra and tocilizumab in anticytokine therapy in the treatment of coronavirus disease-2019. Indian J Crit Care Med 2022;26(10):1091–1098.
  13. Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della–Torre E, De Luca G, et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: A cohort study. Lancet Rheumatol 2021; 3(4): e253–e261. DOI:10.1016/S2665-9913(21)00012-6.
  14. Iglesias–Julián E, López–Veloso M, de-la-Torre-Ferrera N, Barraza–Vengoechea JC, Delgado–López PD, Colazo–Burlato M, et al. High dose subcutaneous anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients. J Autoimmun 2020;115:102537. DOI: 10.1016/j.jaut.2020.102537.
  15. Langer–Gould A, Smith JB, Gonzales EG, Castillo RD, Figueroa JG, Ramanathan A, et al. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. Int J Infect Dis 2020; 99:291–297. DOI: 10.1016/j.ijid.2020.07.081.
  16. European Respiratory Society. COVID-19 guidelines and recommendations directory. Available at: https://www.ersnet.org/covid-19/covid-19-guidelines-and-recommendations-directory/ Accessed on: 10 September 2022.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.